Jong Gwang Kim

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Yoon‐Koo Kang, Jeong Hwan Yook, Young-Kyu Park et al. · Journal of Clinical Oncology · 2021 · 355 citations · Full text

Medicine, Oncology, Surgery +17

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Li‐Tzong Chen, Taroh Satoh, Min‐Hee Ryu et al. · Gastric Cancer · 2019 · 231 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park et al. · The Lancet Oncology · 2020 · 190 citations

Medicine, Oncology, Pharmacology +16

Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer

Min‐Hee Ryu, Changhoon Yoo, Jong Gwang Kim et al. · European Journal of Cancer · 2015 · 129 citations

Medicine, Oncology, Pharmacology +14